Cargando…
Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
Objective: To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods: Patients previously treated with belimumab self-administered belimumab 200 mg SC weekly for 8 weeks using an autoinjector. The primary endpoi...
Autores principales: | Sheikh, Saira Z., Hammer, Anne E., Fox, Norma Lynn, Groark, James, Struemper, Herbert, Roth, David, Gordon, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100660/ https://www.ncbi.nlm.nih.gov/pubmed/27668697 http://dx.doi.org/10.5414/CP202623 |
Ejemplares similares
-
Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects
por: Struemper, Herbert, et al.
Publicado: (2015) -
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017) -
Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus
por: Dashiell-Aje, Ebony, et al.
Publicado: (2017) -
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
por: Stohl, William, et al.
Publicado: (2017) -
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
por: Yapa, S Wickramaratne Senarath, et al.
Publicado: (2016)